All In Biotech

NDA 022445 · Heron Theraps INC

Sustol

Granisetron · Subcutaneous · Serotonin-3 Receptor Antagonist

Discontinued

Last checked: Nov 20, 2026Latest source record: Feb 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Aug 9, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

124

32 Phase 3, 5 recruiting

FAERS reports

8,930

8,044 serious, 1,558 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 30, 2026.

SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. ( 1 )

Mechanism: Granisetron is a selective 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT 1 , 5-HT 1A , 5-HT 1B/C , 5-HT 2 ; for alpha 1- , alpha 2- , or beta-adrenoreceptors; for dopamine-D 2 ; or for histamine-H 1 ; benzodiazepine; picrotoxin or opioid receptors. Serotonin receptors of the 5-HT 3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 9, 2016 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • SUSTOL · GRANISETRON 10MG/0.4ML (10MG/0.4ML) · INJECTABLE, SUBCUTANEOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Granisetron" as an intervention, any sponsor and status, largest first.

All 124 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea1,069
  • febrile neutropenia724
  • vomiting673
  • diarrhoea665
  • pyrexia622
  • dyspnoea580
  • fatigue508
  • anaemia471
  • neutropenia461
  • off label use440
  • death346
  • general physical health deterioration346

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004129
2005106
200660
200774
200863
200953
2010123
2011242
2012621
2013366
2014421
2015431
2016654
2017568
2018701
2019619
2020603
2021721
2022680
2023481
2024441
2025476
2026296

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sustol (Granisetron)

2024 spending

$112K

Beneficiaries

38

123 claims

Per beneficiary

$2,938

$1,848.35 per unit

View as table
YearSpending
2020$22,961
2021$45,064
2022$95,217
2023$88,320
2024$111,640

Part B: Sustol (Granisetron) · HCPCS J1627

2024 spending

$6.6M

Beneficiaries

2,665

12,286 claims

Per beneficiary

$2,488

2024 ASP limit $5.61 per unit

View as table
YearSpending
2020$1,243,201
2021$3,490,060
2022$4,424,281
2023$6,552,162
2024$6,629,675

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 568 on PubMed

Sponsor: Heron Theraps INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.